Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Rocket Pharmaceuticals, Inc. +2.64% Pre
Rocket Pharmaceuticals, Inc. RCKT | 17.49 17.49 | +2.64% 0.00% Pre |
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:
RCKT) with a Buy and maintains $62 price target.